Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from EZH1/2 inhibition selectively targets SMARCA4/2 co-deficient lung cancer cells by suppressing stemness and proliferation. Local targets link to admitted publications; unresolved targets remain external evidence.
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
10.1038/ng.3399 · 2015 · External reference
The 2021 WHO classification of lung tumors: impact of advances since 2015
10.1016/j.jtho.2021.11.003 · 2022 · External reference
Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
10.1038/modpathol.2017.11 · 2017 · External reference
SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses
10.1097/pas.0000000000001188 · 2019 · External reference
Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
10.1016/j.gde.2017.02.004 · 2017 · External reference
SWI/SNF nucleosome remodellers and cancer
10.1038/nrc3068 · 2011 · External reference
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
10.1038/ng.2628 · 2013 · External reference
SMARCA4-Deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
10.1016/j.jtho.2019.10.023 · 2020 · External reference
The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer
10.1158/1078-0432.ccr-20-1825 · 2020 · External reference
SMARCA4 and SMARCA2 co-deficiency: an uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling
10.1016/j.canlet.2024.217282 · 2024 · External reference
The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity–independent genomic targeting
10.1038/s41588-019-0363-5 · 2019 · External reference
Brief report: clinical characteristics and outcomes of patients with thoracic SMARCA4-deficient undifferentiated tumors
2025 · External reference
Thoracic SMARCA4-deficient undifferentiated tumor prone to misdiagnosis as lung adenocarcinoma: a case report and literature review
2026 · External reference
Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor
10.1002/path.6141 · 2023 · External reference
Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies
10.1158/1078-0432.ccr-23-2360 · 2024 · External reference
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation
10.1016/j.ccr.2010.09.006 · 2010 · External reference
Dynamics of BAF-polycomb complex opposition on heterochromatin in normal and oncogenic states
10.1038/ng.3734 · 2017 · External reference
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency
10.1016/j.molcel.2008.10.016 · 2008 · External reference
Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models
10.1158/1535-7163.mct-16-0678 · 2017 · External reference
PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
10.1073/pnas.1703966114 · 2017 · External reference
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
10.1073/pnas.1303800110 · 2013 · External reference
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
10.1016/s1470-2045(20)30451-4 · 2020 · External reference
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
10.1016/j.omto.2022.09.006 · 2022 · External reference
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
10.1111/cas.13326 · 2017 · External reference
ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays
10.1371/journal.pone.0092444 · 2014 · External reference
Unresolved reference
2024 · External reference
Next-generation characterization of the cancer cell line encyclopedia
10.1038/s41586-019-1186-3 · 2019 · External reference
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
10.1093/bioinformatics/btw313 · 2016 · External reference
Chromatin accessibility profiling by ATAC-seq
10.1038/s41596-022-00692-9 · 2022 · External reference
STAR: ultrafast universal RNA-seq aligner
10.1093/bioinformatics/bts635 · 2013 · External reference
Salmon provides fast and bias-aware quantification of transcript expression
10.1038/nmeth.4197 · 2017 · External reference
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
10.1186/s13059-014-0550-8 · 2014 · External reference
Gene set knowledge discovery with Enrichr
10.1002/cpz1.90 · 2021 · External reference
clusterProfiler 4.0: a universal enrichment tool for interpreting omics data
2021 · External reference
Fast gene set enrichment analysis
2021 · External reference
The molecular signatures database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Fast and accurate short read alignment with burrows-wheeler transform
10.1093/bioinformatics/btp324 · 2009 · External reference
Model-based analysis of ChIP-Seq (MACS)
10.1186/gb-2008-9-9-r137 · 2008 · External reference
deepTools2: a next generation web server for deep-sequencing data analysis
10.1093/nar/gkw257 · 2016 · External reference
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
10.1016/j.molcel.2010.05.004 · 2010 · External reference
SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation
10.1038/ng.3746 · 2017 · External reference
Targeting EZH2 in cancer
10.1038/nm.4036 · 2016 · External reference
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
10.1093/emboj/cdg542 · 2003 · External reference
The polycomb complex PRC2 and its mark in life
10.1038/nature09784 · 2011 · External reference
AP-1 transcription factors and the BAF complex mediate signal-dependent enhancer selection
10.1016/j.molcel.2017.11.026 · 2017 · External reference
Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism
10.7554/elife.59073 · 2020 · External reference
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma
10.1038/nature13305 · 2014 · External reference
Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells
10.1038/ncb1589 · 2007 · External reference
Abstract 7055: synergistic effects of HM97662 as an EZH1/2 dual inhibitor combined with DNA-damaging agents on malignant lung cancers harboring SMARCA4-deficiency
10.1158/1538-7445.am2026-7055 · 2026 · External reference
976P HM97662, a novel EZH1/2 dual inhibitor, in patients with advanced or metastatic solid tumors: initial results from a first-in-human phase I study
10.1016/j.annonc.2025.08.1545 · 2025 · External reference
